Trastuzumab emtansine

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (HY-19792) . Trastuzumab emtansine can be used for the research of advanced breast cancer[1][2].

Product Specifications

CAS Number

[1018448-65-1]

Product Name Alternative

Ado-Trastuzumab emtansine; PRO132365; T-DM 1

UNSPSC

12352203

Hazard Statement

H300-H315-H330-H340-H351-H360-H371

Target

Antibody-Drug Conjugates (ADCs) ; EGFR

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/trastuzumab-emtansine.html

Purity

99.74

Solubility

H2O

Smiles

[Trastuzumabemtansine]

Molecular Weight

148000 (average)

Precautions

P260-P264-P270-P271-P280-P284-P302+P352-P304+P340-P308+P311-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Verma S, et, al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367 (19) :1783-91.|[2]Menderes G, et, al. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecol Oncol. 2017 Oct;147 (1) :145-152.